<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32408605</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Brain Protease Activated Receptor 1 Pathway: A Therapeutic Target in the Superoxide Dismutase 1 (SOD1) Mouse Model of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21103419</ELocationID><Abstract><AbstractText>Glia cells are involved in upper motor neuron degeneration in amyotrophic lateral sclerosis (ALS). Protease activated receptor 1 (PAR1) pathway is related to brain pathologies. Brain PAR1 is located on peri-synaptic astrocytes, adjacent to pyramidal motor neurons, suggesting possible involvement in ALS. Brain thrombin activity in superoxide dismutase 1 (SOD1) mice was measured using a fluorometric assay, and PAR1 levels by western blot. PAR1 was localized using immunohistochemistry staining. Treatment targeted PAR1 pathway on three levels; thrombin inhibitor TLCK (N-Tosyl-Lys-chloromethylketone), PAR1 antagonist SCH-79797 and the Ras intracellular inhibitor FTS (<i>S</i>-trans-trans-farnesylthiosalicylic acid). Mice were weighed and assessed for motor function and survival. SOD1 brain thrombin activity was increased (<i>p</i> &lt; 0.001) particularly in the posterior frontal lobe (<i>p</i> = 0.027) and hindbrain (<i>p</i> &lt; 0.01). PAR1 levels were decreased (<i>p</i> &lt; 0.001, brain, spinal cord, <i>p</i> &lt; 0.05). PAR1 and glial fibrillary acidic protein (GFAP) staining decreased in the cerebellum and cortex. SOD1 mice lost weight (&#x2265;17 weeks, <i>p</i> = 0.047), and showed shorter rotarod time (&#x2265;14 weeks, <i>p</i> &lt; 0.01). FTS 40mg/kg significantly improved rotarod scores (<i>p</i> &lt; 0.001). Survival improved with all treatments (<i>p</i> &lt; 0.01 for all treatments). PAR1 antagonism was the most efficient, with a median survival improvement of 10 days (<i>p</i> &lt; 0.0001). Our results support PAR1 pathway involvement in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shavit-Stein</LastName><ForeName>Efrat</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3373-8397</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Rahal</LastName><ForeName>Ihab</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bushi</LastName><ForeName>Doron</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gera</LastName><ForeName>Orna</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharon</LastName><ForeName>Roni</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2452-8921</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gofrit</LastName><ForeName>Shany G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0001-6104-606X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mindel</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggio</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloog</LastName><ForeName>Yoel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurobiochemistry, Weiss Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Joab</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Robert and Martha Harden Chair in Mental and Neurological Diseases, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dori</LastName><ForeName>Amir</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4633-1481</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan 52626202, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C415424">N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044463">Receptor, PAR-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012459">Salicylates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C093323">farnesylthiosalicylic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>2104-86-1</RegistryNumber><NameOfSubstance UI="D014107">Tosyllysine Chloromethyl Ketone</NameOfSubstance></Chemical><Chemical><RegistryNumber>4602-84-0</RegistryNumber><NameOfSubstance UI="D005204">Farnesol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005204" MajorTopicYN="N">Farnesol</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044463" MajorTopicYN="N">Receptor, PAR-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012459" MajorTopicYN="N">Salicylates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014107" MajorTopicYN="N">Tosyllysine Chloromethyl Ketone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">brain</Keyword><Keyword MajorTopicYN="N">protease activated receptor 1 (PAR1)</Keyword><Keyword MajorTopicYN="N">superoxide dismutase 1 (SOD1)</Keyword><Keyword MajorTopicYN="N">thrombin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32408605</ArticleId><ArticleId IdType="pmc">PMC7279358</ArticleId><ArticleId IdType="doi">10.3390/ijms21103419</ArticleId><ArticleId IdType="pii">ijms21103419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A., Hardiman O., Kiernan M.C., Chi&#xf2; A., Rix-Brooks B., van den Berg L.H. Amyotrophic lateral sclerosis: Moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland L.P. Diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;160:S6&#x2013;S24. doi: 10.1016/S0022-510X(98)00193-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00193-2</ArticleId><ArticleId IdType="pubmed">9851643</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A.E., Ferraiuolo L., Haidet-Phillips A.M., Schmelzer L., Braun L., Miranda C.J., Ladner K.J., Bevan A.K., Foust K.D., Godbout J.P., et al. Microglia Induce Motor Neuron Death via the Classical NF-&#x3ba;B Pathway in Amyotrophic Lateral Sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Glial cells in amyotrophic lateral sclerosis. Exp. Neurol. 2014;262:111&#x2013;120. doi: 10.1016/j.expneurol.2014.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.05.015</ArticleId><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P., Corcia P., Lautrette G., Nicol M., Preux P.M., Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. Rev. Neurol. (Paris) 2016;172:37&#x2013;45. doi: 10.1016/j.neurol.2015.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2015.11.002</ArticleId><ArticleId IdType="pubmed">26727307</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 1995;92:689&#x2013;693. doi: 10.1073/pnas.92.3.689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.3.689</ArticleId><ArticleId IdType="pmc">PMC42685</ArticleId><ArticleId IdType="pubmed">7846037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton J.B., Mercer S.W., Lim N.K.H., Faux N.G., Buncic G., Beckman J.S., Roberts B.R., Donnelly P.S., White A.R., Crouch P.J. CuII (atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. 2017;7:42292. doi: 10.1038/srep42292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42292</ArticleId><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y., Homma K., Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv. Biol. Regul. 2016;60:95&#x2013;104. doi: 10.1016/j.jbior.2015.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.10.006</ArticleId><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M.J., Z&#xfc;rcher N.R., Loggia M.L., Cernasov P., Chonde D.B., Izquierdo Garcia D., Yasek J.E., Akeju O., Catana C., Rosen B.R., et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87:2554&#x2013;2561. doi: 10.1212/WNL.0000000000003427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003427</ArticleId><ArticleId IdType="pmc">PMC5207001</ArticleId><ArticleId IdType="pubmed">27837005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland L.G., Nirmalananthan N., Yip J., Greensmith L., Duchen M.R. Expression of mutant SOD1G93A in astrocytes induces functional deficits in motoneuron mitochondria. J. Neurochem. 2008;107:1271&#x2013;1283. doi: 10.1111/j.1471-4159.2008.05699.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05699.x</ArticleId><ArticleId IdType="pubmed">18808448</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Madji Hounoum B., Mavel S., Coque E., Patin F., Vourc&#x2019;h P., Marouillat S., Nadal-Desbarats L., Emond P., Corcia P., Andres C.R., et al. Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia. 2017;65:592&#x2013;605. doi: 10.1002/glia.23114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23114</ArticleId><ArticleId IdType="pubmed">28139855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabham P., Cunningham D.D. Thrombin Receptor Activation Stimulates Astrocyte Proliferation and Reversal of Stellation by Distinct Pathways: Involvement of Tyrosine Phosphorylation. J. Neurochem. 1995;64:583&#x2013;591. doi: 10.1046/j.1471-4159.1995.64020583.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1995.64020583.x</ArticleId><ArticleId IdType="pubmed">7830051</ArticleId></ArticleIdList></Reference><Reference><Citation>Gofrit S., Shavit-Stein E. The neuro-glial coagulonome: The thrombin receptor and coagulation pathways as major players in neurological diseases. Neural Regen. Res. 2019;14:2043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6788244</ArticleId><ArticleId IdType="pubmed">31397331</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidlin F., Bunnett N.W. Protease-activated receptors: How proteases signal to cells. Curr. Opin. Pharmacol. 2001;1:575&#x2013;582. doi: 10.1016/S1471-4892(01)00099-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4892(01)00099-6</ArticleId><ArticleId IdType="pubmed">11757812</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A., Soh U.J.K., Trejo J. Proteases display biased agonism at protease-activated receptors: Location matters. Mol. Interv. 2009;9:87&#x2013;96. doi: 10.1124/mi.9.2.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mi.9.2.8</ArticleId><ArticleId IdType="pmc">PMC3139377</ArticleId><ArticleId IdType="pubmed">19401541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z., Ilieva H., Hallagan L., Bell R., Singh I., Paquette N., Thiyagarajan M., Deane R., Fernandez J.A., Lane S., et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J. Clin. Invest. 2009;119:3437&#x2013;3449. doi: 10.1172/JCI38476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI38476</ArticleId><ArticleId IdType="pmc">PMC2769191</ArticleId><ArticleId IdType="pubmed">19841542</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuberger D.M., Schuepbach R.A. Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb. J. 2019;17:4. doi: 10.1186/s12959-019-0194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-019-0194-8</ArticleId><ArticleId IdType="pmc">PMC6440139</ArticleId><ArticleId IdType="pubmed">30976204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis C.A., Malik A.B., Gilchrist A., Hamm H., Sandoval R., Voyno-Yasenetskaya T., Tiruppathi C. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway. J. Biol. Chem. 1999;274:13718&#x2013;13727. doi: 10.1074/jbc.274.19.13718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.19.13718</ArticleId><ArticleId IdType="pubmed">10224146</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavit E., Michaelson D.M., Chapman J. Anatomical localization of protease-activated receptor-1 and protease-mediated neuroglilal crosstalk on peri-synaptic astrocytic endfeet. J. Neurochem. 2011;119:460&#x2013;473. doi: 10.1111/j.1471-4159.2011.07436.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07436.x</ArticleId><ArticleId IdType="pubmed">21854391</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurwitz D., Korczyn A.D., Beilin O., Karussis D.M., Aronovich R., Mizrachi-Kol R., Hantai D., Chapman J., Grigoriadis N. Increased thrombin inhibition in experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2004;79:351&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15605378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Shimon M., Zeimer T., Shavit Stein E., Artan-Furman A., Harnof S., Chapman J., Eisenkraft A., Pick C.G., Maggio N. Recovery from trauma induced amnesia correlates with normalization of thrombin activity in the mouse hippocampus. PLoS ONE. 2017;12:e0188524. doi: 10.1371/journal.pone.0188524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188524</ArticleId><ArticleId IdType="pmc">PMC5705129</ArticleId><ArticleId IdType="pubmed">29182653</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio N., Cavaliere C., Papa M., Blatt I., Chapman J., Segal M. Thrombin regulation of synaptic transmission: Implications for seizure onset. Neurobiol. Dis. 2013;50:171&#x2013;178. doi: 10.1016/j.nbd.2012.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.10.017</ArticleId><ArticleId IdType="pubmed">23103417</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavit-Stein E., Sheinberg E., Golderman V., Sharabi S., Wohl A., Gofrit S.G., Zivli Z., Shelestovich N., Last D., Guez D., et al. A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma. Front. Neurol. 2018;9:1087. doi: 10.3389/fneur.2018.01087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01087</ArticleId><ArticleId IdType="pmc">PMC6304418</ArticleId><ArticleId IdType="pubmed">30619047</ArticleId></ArticleIdList></Reference><Reference><Citation>Festoff B.W., D&#x2019;Andrea M.R., Citron B.A., Salcedo R.M., Smirnova I.V., Andrade-Gordon P. Motor neuron cell death in wobbler mutant mice follows overexpression of the G-protein-coupled, protease-activated receptor for thrombin. Mol. Med. 2000;6:410&#x2013;429. doi: 10.1007/BF03401784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03401784</ArticleId><ArticleId IdType="pmc">PMC1949954</ArticleId><ArticleId IdType="pubmed">10952021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovich-Toidman P., Rabinovich-Nikitin I., Ezra A., Barbiro B., Fogel H., Slutsky I., Solomon B. Mutant SOD1 increases APP expression and phosphorylation in cellular and animal models of ALS. PLoS ONE. 2015;10:e0143420. doi: 10.1371/journal.pone.0143420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143420</ArticleId><ArticleId IdType="pmc">PMC4658003</ArticleId><ArticleId IdType="pubmed">26600047</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.A., Sengillo J.D., Sullivan J.S., Henkel J.S., Appel S.H., Zlokovic B.V. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:111&#x2013;120. doi: 10.1007/s00401-012-1039-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein E.S., Itsekson-Hayosh Z., Aronovich A., Reisner Y., Bushi D., Pick C.G., Tanne D., Chapman J., Vlachos A., Maggio N. Thrombin induces ischemic LTP (iLTP): Implications for synaptic plasticity in the acute phase of ischemic stroke. Sci. Rep. 2015;5:7912. doi: 10.1038/srep07912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07912</ArticleId><ArticleId IdType="pmc">PMC4300504</ArticleId><ArticleId IdType="pubmed">25604482</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Sanberg P.R. Blood-CNS barrier impairment in ALS patients versus an animal model. Front. Cell. Neurosci. 2014;8:21. doi: 10.3389/fncel.2014.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00021</ArticleId><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Andjus P.R., Batavelji&#x107; D., Vanhoutte G., Mitrecic D., Pizzolante F., Djogo N., Nicaise C., Kengne F.G., Gangitano C., Michetti F., et al. In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer&#x2019;s-like disease: MRI approach. Anat. Rec. (Hoboken) 2009;292:1882&#x2013;1892. doi: 10.1002/ar.20995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.20995</ArticleId><ArticleId IdType="pubmed">19943341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushi D., Ben Shimon M., Shavit Stein E., Chapman J., Maggio N., Tanne D. Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus. J. Neurochem. 2015;135:1140&#x2013;1148. doi: 10.1111/jnc.13372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13372</ArticleId><ArticleId IdType="pubmed">26390857</ArticleId></ArticleIdList></Reference><Reference><Citation>Gera O., Shavit-Stein E., Bushi D., Harnof S., Shimon M.B., Weiss R., Golderman V., Dori A., Maggio N., Finegold K., et al. Thrombin and protein C pathway in peripheral nerve Schwann cells. Neuroscience. 2016;339:587&#x2013;598. doi: 10.1016/j.neuroscience.2016.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2016.10.034</ArticleId><ArticleId IdType="pubmed">27771530</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavit-Stein E., Aronovich R., Sylantiev C., Gofrit S.G., Chapman J., Dori A. The role of thrombin in the pathogenesis of diabetic neuropathy. PLoS ONE. 2019;14:e0219453. doi: 10.1371/journal.pone.0219453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0219453</ArticleId><ArticleId IdType="pmc">PMC6611599</ArticleId><ArticleId IdType="pubmed">31276565</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavit-Stein E., Aronovich R., Sylantiev C., Gera O., Gofrit S.G., Chapman J., Dori A. Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis. Front. Neurol. 2019;9:1139. doi: 10.3389/fneur.2018.01139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01139</ArticleId><ArticleId IdType="pmc">PMC6328627</ArticleId><ArticleId IdType="pubmed">30662428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushi D., Stein E.S., Golderman V., Feingold E., Gera O., Chapman J., Tanne D. A linear temporal increase in thrombin activity and loss of its receptor in mouse brain following ischemic stroke. Front. Neurol. 2017;8:138. doi: 10.3389/fneur.2017.00138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00138</ArticleId><ArticleId IdType="pmc">PMC5385331</ArticleId><ArticleId IdType="pubmed">28443061</ArticleId></ArticleIdList></Reference><Reference><Citation>Itsekson-Hayosh Z., Shavit-Stein E., Katzav A., Rubovitch V., Maggio N., Chapman J., Harnof S., Pick C.G. Minimal Traumatic Brain Injury in Mice: Protease-Activated Receptor 1 and Thrombin-Related Changes. J. Neurotrauma. 2016;33:1848&#x2013;1854. doi: 10.1089/neu.2015.4146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2015.4146</ArticleId><ArticleId IdType="pubmed">26537880</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin S.R. How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. USA. 1999;96:11023&#x2013;11027. doi: 10.1073/pnas.96.20.11023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11023</ArticleId><ArticleId IdType="pmc">PMC34235</ArticleId><ArticleId IdType="pubmed">10500117</ArticleId></ArticleIdList></Reference><Reference><Citation>Festoff B.W., Citron B.A. Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders. Front. Neurol. 2019;10:59. doi: 10.3389/fneur.2019.00059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00059</ArticleId><ArticleId IdType="pmc">PMC6371052</ArticleId><ArticleId IdType="pubmed">30804878</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio N., Shavit E., Chapman J., Segal M. Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: Toward understanding the functional consequences of cerebrovascular insults. J. Neurosci. 2008;28:732&#x2013;736. doi: 10.1523/JNEUROSCI.3665-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3665-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670357</ArticleId><ArticleId IdType="pubmed">18199772</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzekson Z., Maggio N., Milman A., Shavit E., Pick C.G., Chapman J. Reversal of trauma-induced amnesia in mice by a thrombin receptor antagonist. J. Mol. Neurosci. 2014;53:87&#x2013;95. doi: 10.1007/s12031-013-0200-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-013-0200-8</ArticleId><ArticleId IdType="pubmed">24352712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosche J., Kettenmann H., Reichenbach A. Bergmann glial cells form distinct morphological structures to interact with cerebellar neurons. J. Neurosci. Res. 2002;68:138&#x2013;149. doi: 10.1002/jnr.10197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10197</ArticleId><ArticleId IdType="pubmed">11948659</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshar P., Ashtari N., Jiao X., Rahimi-Balaei M., Zhang X., Yaganeh B., Del Bigio M.R., Kong J., Marzban H. Overexpression of human SOD1 leads to discrete defects in the cerebellar architecture in the mouse. Front. Neuroanat. 2017;11:22. doi: 10.3389/fnana.2017.00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2017.00022</ArticleId><ArticleId IdType="pmc">PMC5372795</ArticleId><ArticleId IdType="pubmed">28424594</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis N., Lau C.L., Farg M.A., Atkin J.D., Beart P.M., O&#x2019;Shea R.D. SOD1 Mutations Causing Familial Amyotrophic Lateral Sclerosis Induce Toxicity in Astrocytes: Evidence for Bystander Effects in a Continuum of Astrogliosis. Neurochem. Res. 2018;43:157&#x2013;170. doi: 10.1007/s11064-017-2385-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-017-2385-7</ArticleId><ArticleId IdType="pubmed">28861673</ArticleId></ArticleIdList></Reference><Reference><Citation>Almad A.A., Doreswamy A., Gross S.K., Richard J.P., Huo Y., Haughey N., Maragakis N.J. Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia. 2016;64:1154&#x2013;1169. doi: 10.1002/glia.22989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22989</ArticleId><ArticleId IdType="pmc">PMC5635605</ArticleId><ArticleId IdType="pubmed">27083773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M., Chi&#xf2; A., Valentini M.C., &#xd6;berg J., Nobili F., Calvo A., Moglia C., Bertuzzo D., Morbelli S., De Carli F., et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Valentini M.C., Chi&#xf2; A., Nobili F., Calvo A., Moglia C., Montuschi A., Morbelli S., Salmaso D., Fania P., et al. Brain hypermetabolism in amyotrophic lateral sclerosis: A FDG PET study in ALS of spinal and bulbar onset. Eur. J. Nucl. Med. Mol. Imaging. 2012;39:251&#x2013;259. doi: 10.1007/s00259-011-1979-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1979-6</ArticleId><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T., Grosskreutz J. The involvement of the cerebellum in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2013;14:507&#x2013;515. doi: 10.3109/21678421.2013.812661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.812661</ArticleId><ArticleId IdType="pubmed">23889583</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill C., Phelan J.P., Hatzipetros T., Kidd J.D., Tassinari V.R., Levine B., Wang M.Z., Moreno A., Thompson K., Maier M., et al. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci. Rep. 2019;9:1&#x2013;13. doi: 10.1038/s41598-019-43164-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-43164-z</ArticleId><ArticleId IdType="pmc">PMC6491559</ArticleId><ArticleId IdType="pubmed">31040321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W.L., Tian F., Zhang S.Q., Zhang H., Yin Z.S. Epidermal growth factor increases the expression of Nestin in rat reactive astrocytes through the Ras-Raf-ERK pathway. Neurosci. Lett. 2014;562:54&#x2013;59. doi: 10.1016/j.neulet.2014.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.01.018</ArticleId><ArticleId IdType="pubmed">24462842</ArticleId></ArticleIdList></Reference><Reference><Citation>Samatar A.A., Poulikakos P.I. Targeting RAS&#x2013;ERK signalling in cancer: Promises and challenges. Nat. Rev. Drug Discov. 2014;13:928&#x2013;942. doi: 10.1038/nrd4281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4281</ArticleId><ArticleId IdType="pubmed">25435214</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamino T., Yoshida T., Tateno K., Miyauchi H., Zou Y., Toko H., Komuro I. Ras Induces Vascular Smooth Muscle Cell Senescence and Inflammation in Human Atherosclerosis. Circulation. 2003;108:2264&#x2013;2269. doi: 10.1161/01.CIR.0000093274.82929.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000093274.82929.22</ArticleId><ArticleId IdType="pubmed">14557365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor A., Philips M.R., Pillinger M.H. The role of Ras signaling in lupus T lymphocytes: Biology and pathogenesis. Clin. Immunol. 2007;125:215&#x2013;223. doi: 10.1016/j.clim.2007.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2007.08.008</ArticleId><ArticleId IdType="pubmed">17913587</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzav A., Kloog Y., Korczyn A.D., Niv H., Karussis D.M., Wang N., Rabinowitz R., Blank M., Shoenfeld Y., Chapman J. Treatment of MRL/lpr mice, a genetic autoimmune model, with the ras inhibitor, farnesylthiosalicylate (FTS) Clin. Exp. Immunol. 2001;126:570&#x2013;577. doi: 10.1046/j.1365-2249.2001.01674.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2001.01674.x</ArticleId><ArticleId IdType="pmc">PMC1906212</ArticleId><ArticleId IdType="pubmed">11737078</ArticleId></ArticleIdList></Reference><Reference><Citation>Karussis D., Abramsky O., Grigoriadis N., Chapman J., Mizrachi-Koll R., Niv H., Kloog Y. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. 2001;120:1&#x2013;9. doi: 10.1016/S0165-5728(01)00385-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(01)00385-X</ArticleId><ArticleId IdType="pubmed">11694313</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan C.-P., Chang M.-C., Wang Y.-J., Chen L.-I., Tsai Y.-L., Lee J.-J., Jia H.-W., Jeng J.-H. Thrombin Activates Ras-CREB/ATF-1 Signaling and Stimulates c-fos, c-jun, and c-myc Expression in Human Gingival Fibroblasts. J. Periodontol. 2008;79:1248&#x2013;1254. doi: 10.1902/jop.2008.070523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1902/jop.2008.070523</ArticleId><ArticleId IdType="pubmed">18597608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.H., Joo K.M., Lim H.C., Cho M.H., Kim D., Lee W.B., Cha C.I. Immunohistochemical study on the distribution of phosphorylated extracellular signal-regulated kinase (ERK) in the central nervous system of SOD1G93A transgenic mice. Brain Res. 2005;1050:203&#x2013;209. doi: 10.1016/j.brainres.2005.05.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.05.060</ArticleId><ArticleId IdType="pubmed">15978558</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.W., Chen S.W.C., Kim M., D&#x2019;Agati V.D., Lee H.T. Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice. Kidney Int. 2009;76:739&#x2013;750. doi: 10.1038/ki.2009.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2009.255</ArticleId><ArticleId IdType="pubmed">19625989</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow D.A., Alberts M.J., Mohr J.P., Ameriso S.F., Bonaca M.P., Goto S., Hankey G.J., Murphy S.A., Scirica B.M., Braunwald E. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44:691&#x2013;698. doi: 10.1161/STROKEAHA.111.000433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.000433</ArticleId><ArticleId IdType="pubmed">23396280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushi D., Chapman J., Katzav A., Shavit-Stein E., Molshatzki N., Maggio N., Tanne D. Quantitative detection of thrombin activity in an ischemic stroke model. J. Mol. Neurosci. 2013;51:844&#x2013;850. doi: 10.1007/s12031-013-0072-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-013-0072-y</ArticleId><ArticleId IdType="pubmed">23900720</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;nther R., Suhr M., Koch J.C., B&#xe4;hr M., Lingor P., T&#xf6;nges L. Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS) J. Vis. Exp. 2012;17:e3936. doi: 10.3791/3936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/3936</ArticleId><ArticleId IdType="pmc">PMC3415170</ArticleId><ArticleId IdType="pubmed">22453893</ArticleId></ArticleIdList></Reference><Reference><Citation>Oron T., Elad-Sfadia G., Haklai R., Aizman E., Brazowski E., Kloog Y., Reif S. Prevention of induced colitis in mice by the Ras antagonist farnesylthiosalicylic acid. Dig. Dis. Sci. 2012;57:320&#x2013;326. doi: 10.1007/s10620-011-1880-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-011-1880-y</ArticleId><ArticleId IdType="pubmed">21901261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>